Adma biologics director Jerrold Grossman buys $100,125 in stock
Jerrold B. Grossman, a director at ADMA Biologics, Inc., recently purchased 12,500 shares of the company's common stock for $100,125, at a price of $8.01 per share. This transaction occurred on May 12, 2026, when the stock was trading near its 52-week low, and follows a recent earnings report where the company missed analyst expectations. Grossman's direct and indirect holdings now total a significant number of shares, indicating his continued investment in the company.
How this was made
The 30-second read
Why it matters
The purchase occurred when the stock was near its 52-week low, possibly indicating confidence in a future rebound despite recent earnings disappointment.
Market read
Insider buying activity can be a positive signal but should be considered alongside recent earnings performance and technical indicators.
What to watch
Recent earnings miss and stock trading near 52-week low could indicate underlying issues, which insider buying alone does not negate.
Background
Jerrold Grossman, a director at ADMA Biologics, purchased 12,500 shares at $8.01 per share, totaling $100,125, on May 12, 2026.
Ticker impact
High relevance due to insider trading activity and recent stock price behavior.
Moderate upward price movement expected in the short term, with potential for continued growth if insider confidence persists.
Insider buying often indicates positive expectations; however, recent earnings miss and stock near 52-week low introduce some caution.
Market effects
Potential positive sentiment in the biotech and life sciences sectors, especially for companies with similar profiles.
Limited regional impact; specific to US biotech sector.
Low; company-specific event with minimal global market influence.
Counterpoint
Insider buying may be motivated by personal investment strategies unrelated to company fundamentals; caution advised.
Key entities
- CompanyADMA Biologics, Inc.
A biopharmaceutical company focused on plasma-derived therapies.
- PersonJerrold B. Grossman
Director at ADMA Biologics who made the recent stock purchase.
